When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy

Transfusion

Volumn 55, Issue 6, 2015, Pages 1555-1562

  Oostendorp, Marlies ^a   Lammerts Van Bueren, Jeroen J ^b   Doshi, Parul ^c   Khan, Imran ^c   Ahmadi, Tahamtan ^c   Parren, Paul W H I ^b,d   Van Solinge, Wouter W ^a   De Vooght, Karen M K ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b GENMAB   (Netherlands)

^c Janssen RandD LLC   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIIDIOTYPIC ANTIBODY; BLOOD GROUP ANTIBODY; DARATUMUMAB; FRESH FROZEN PLASMA; HEMOGLOBIN; MACROGOL; ANTINEOPLASTIC AGENT; CD38 ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY SCREENING; ANTIGEN ANTIBODY REACTION; ARTICLE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COOMBS TEST; DRUG DOSE ESCALATION; ERYTHROCYTE; FALSE POSITIVE RESULT; FEMALE; FLOW CYTOMETRY; HUMAN; IN VITRO STUDY; INDIRECT ANTIGLOBULIN TEST; LOW DRUG DOSE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RETICULOCYTE COUNT; TRANSFUSION MEDICINE; AGED; BLOOD; BLOOD GROUP TYPING; CROSS REACTION; HEK293 CELL LINE; IMMUNOLOGY; LABORATORY DIAGNOSIS; PROCEDURES; SEROLOGY; STANDARDS;

AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD38; ANTINEOPLASTIC AGENTS; BLOOD GROUPING AND CROSSMATCHING; BLOOD TRANSFUSION; COOMBS TEST; CROSS REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HEK293 CELLS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; SEROLOGIC TESTS;

EID: 84931563891     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13150     Document Type: Article

References (13)

1. Young D,. Effects of drugs on clinical laboratory tests. 5th ed. Washington, DC: AACC Press; 2000.
2. Ruuls SR, Lammerts van Bueren JJ, van de Winkel JG, et al., Novel human antibody therapeutics: the age of the Umabs. Biotechnol J 2008; 3: 1157-71.
3. Genzen JR, Kawaguchi KR, Furman RR,. Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis. Br J Haematol 2011; 155: 123-5.
4. McCudden CR, Voorhees PM, Hainsworth SA, et al., Interference of monoclonal antibody therapies with serum protein electrophoresis tests. Clin Chem 2010; 56: 1897-9.
5. de Weers M, Tai YT, van der Veer MS, et al., Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186: 1840-8.
6. van der Veer MS, de Weers M, van Kessel B, et al., The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J 2011; 1: e41.
7. van der Veer MS, de Weers M, van Kessel B, et al., Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 2011; 96: 284-90.
8. Vink T, Oudshoorn-Dickmann M, Roza M, et al., A simple, robust and highly efficient transient expression system for producing antibodies. Methods 2014; 65: 5-10.
9. Lammerts van Bueren JJ, Bleeker WK, Bøgh HO, et al,. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res 2006; 66: 7630-8.
10. Albeniz I, Demir O, Türker-Sener L, et al., Erythrocyte CD38 as a prognostic marker in cancer. Hematology 2007; 12: 409-14.
11. Frank MM, Schreiber AD, Atkinson JP, et al., NIH conference. Pathophysiology of immune hemolytic anemia. Ann Intern Med 1977; 87: 210-22.
12. Heddle NM, Soutar RL, O'Hoski PL, et al., A prospective study to determine the frequency and clinical significance of alloimmunization post-transfusion. Br J Haematol 1995; 91: 1000-5.
13. Schonewille H, Haak HL, van Zijl AM,. Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases. Transfusion 1999; 39: 763-71.